$1.67
3.09% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
IL0011050551
Symbol
EVGN
Sector
Industry

Evogene Ltd Stock price

$1.67
-0.79 32.11% 1M
-6.53 79.63% 6M
-6.73 80.12% YTD
-3.96 70.33% 1Y
-18.53 91.73% 3Y
-12.63 88.32% 5Y
-85.73 98.09% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.05 3.09%
ISIN
IL0011050551
Symbol
EVGN
Sector
Industry

Key metrics

Market capitalization $8.96m
Enterprise Value $6.28m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.84
P/S ratio (TTM) P/S ratio 1.20
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 30.69%
Revenue (TTM) Revenue $7.48m
EBIT (operating result TTM) EBIT $-24.75m
Free Cash Flow (TTM) Free Cash Flow $-20.48m
Cash position $19.95m
EPS (TTM) EPS $-4.45
P/E forward negative
P/S forward 0.85
EV/Sales forward 0.60
Short interest 0.42%
Show more

Is Evogene Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Evogene Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Evogene Ltd forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Evogene Ltd forecast:

Buy
100%

Financial data from Evogene Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
7.48 7.48
31% 31%
100%
- Direct Costs 4.90 4.90
15% 15%
66%
2.58 2.58
76% 76%
34%
- Selling and Administrative Expenses 8.53 8.53
22% 22%
114%
- Research and Development Expense 16 16
10% 10%
217%
-22 -22
6% 6%
-296%
- Depreciation and Amortization 2.57 2.57
1% 1%
34%
EBIT (Operating Income) EBIT -25 -25
5% 5%
-331%
Net Profit -24 -24
16% 16%
-314%

In millions USD.

Don't miss a Thing! We will send you all news about Evogene Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evogene Ltd Stock News

Neutral
Seeking Alpha
5 days ago
Evogene Ltd. (NASDAQ:EVGN ) Q3 2024 Earnings Conference Call November 21, 2024 9:00 AM ET Company Participants Ofer Haviv - President and CEO Yaron Eldad - CFO Amit Noam - CEO, Lavie BIO Operator Welcome to Evogene's Third Quarter Results Conference Call.
Neutral
PRNewsWire
5 days ago
Conference call and webcast: today, November 21, 2024, 9:00 am ET Financial Highlights: In the first nine months of 2024, total revenues reached approximately $6.9 million, compared to approximately $5.1 million in the first nine months of 2023. In Q3 2024, total revenues reached approximately $1.8 million, compared to approximately $3.8 million in Q3 2023.
Neutral
PRNewsWire
7 days ago
LAV321demonstrated strong results in its third consecutive year of field trials in Europe REHOVOT, Israel , Nov. 19, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd.
More Evogene Ltd News

Company Profile

Evogene Ltd. operates as a plant genomics company. It utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. It also offers a solution for crop productivity improvement through biotechnology and breeding using a technology infrastructure that is based on deep scientific understanding of plant genomics and proprietary computational capabilities. The company was founded by Amir Barzilay and Hagai Karchi in 2002 and is headquartered in Rehovot, Israel.

Head office Israel
CEO Ofer Haviv
Employees 142
Founded 1999
Website www.evogene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today